3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neuroblastoma
101
Central Nervous System Neoplasms
37
Medulloblastoma
35
Brain Neoplasms
33
Glioblastoma
20
Sarcoma
16
Rhabdoid Tumor
14
Glioma
13
Ependymoma
12
Astrocytoma
11
Osteosarcoma
10
Neuroectodermal Tumors, Primitive
10
Recurrence
9
Neoplasms
9
Lymphoma
9
Breast Neoplasms
9
Sarcoma, Ewing
8
Oligodendroglioma
8
Melanoma
8
Ganglioneuroblastoma
8
Choroid Plexus Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Ovarian Neoplasms
7
Neoplasm Metastasis
7
Lymphoma, Non-Hodgkin
7
Leukemia, Myeloid, Acute
7
Gliosarcoma
7
Rhabdomyosarcoma
6
Multiple Myeloma
6
Wilms Tumor
5
Interventions
trametinib
2
dabrafenib
2
mirdametinib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Vincristine
1
Irinotecan
1
Cyclophosphamide
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ganglioglioma
×
Cyclophosphamide
×
CNS
×
Clear all
NCT03152318
2026-03-04
rQNestin
Dana-Farber Cancer Institute
Phase 1
Active not recruiting
62 enrolled